XML 100 R68.htm IDEA: XBRL DOCUMENT
v3.20.4

Collaboration and Licensing Revenue - Additional Information (Details) | 1 Months Ended | 3 Months Ended | 12 Months Ended | 24 Months Ended |  |  |
--- | --- | --- | --- | --- | --- | --- | ---
Jul. 31, 2020 USD ($) | Mar. 31, 2020 USD ($) | Feb. 29, 2020 USD ($) | Dec. 31, 2018 USD ($) shares | Nov. 30, 2018 USD ($) shares | Oct. 31, 2018 USD ($) quarterly_installment product | Mar. 31, 2016 USD ($) | Dec. 31, 2015 USD ($) | Jun. 30, 2015 USD ($) | Mar. 31, 2015 USD ($) target | Mar. 31, 2014 USD ($) | Oct. 31, 2012 USD ($) | Jan. 31, 2011 USD ($) | Dec. 31, 2020 USD ($) | Sep. 30, 2020 USD ($) | Jun. 30, 2020 USD ($) | Mar. 31, 2020 USD ($) | Dec. 31, 2019 USD ($) | Sep. 30, 2019 USD ($) | Jun. 30, 2019 USD ($) | Mar. 31, 2019 USD ($) | Dec. 31, 2020 USD ($) | Dec. 31, 2019 USD ($) | Dec. 31, 2018 USD ($) | Dec. 31, 2016 USD ($) | Dec. 31, 2013 USD ($) | Dec. 31, 2012 USD ($) | Dec. 31, 2016 USD ($) | Nov. 30, 2020 USD ($) | Sep. 30, 2018 USD ($) | Mar. 01, 2015 USD ($)
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair value of assets |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 48,325,000 |  |  |  | $ 9,260,000 |  |  |  | $ 48,325,000 | $ 9,260,000 |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  | 25,823,000 |  |  |  | 53,833,000 |  |  |  | 25,823,000 | 53,833,000 |  |  |  |  |  |  |  |
Reacquisition of in-process research and development |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | $ 236,748,000 |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  | 19,333,000 | $ 23,583,000 | $ 30,424,000 | $ 29,838,000 | 17,002,000 | $ 18,299,000 | $ 32,836,000 | $ 22,585,000 | $ 103,178,000 | 90,722,000 | 151,178,000 |  |  |  |  |  |  |
Shares issued for reacquired in-process research and development |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 159,323,000 |  |  |  |  |  |  |
Required notice period for voluntary termination of collaborative agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 90 days |  |  |  |  |  |  |  |  |
Licensing agreement between ZIOPHARM and Precigen 2018 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreement, percentage of development costs for which responsible |  |  |  |  |  | 20.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreement, percentage of operating profits to be received |  |  |  |  |  | 20.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreement, annual fee |  |  |  |  |  | $ 100,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreement, reimbursement of historical costs |  |  |  |  |  | $ 1,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreement, reimbursement of historical costs, number of quarterly installments | quarterly_installment |  |  |  |  |  | 4 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments required upon successful achievement, aggregated |  |  |  |  |  | $ 210,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreement, royalty due, aggregated |  |  |  |  |  | $ 100,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreement, percentage of sublicensing income |  |  |  |  |  | 20.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Transition period during which costs will be reimbursed |  |  |  |  |  | 1 year |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreement, termination, period following triggering event |  |  |  |  |  | 12 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 23,420,000 |  |  |  | $ 50,593,000 |  |  |  | $ 23,420,000 | 50,593,000 |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 21,208,000 | 14,059,000 | 69,540,000 |  |  |  |  |  |  |
Upfront and Milestone Payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized from previously deferred balances |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 20,205,000 | 7,505,000 | 39,446,000 |  |  |  |  |  |  |
Maximum | Licensing agreement between ZIOPHARM and Precigen 2018 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments required upon successful achievement, per product |  |  |  |  |  | $ 52,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreement, number of exclusively licensed products | product |  |  |  |  |  | 4 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ZIOPHARM Oncology, Inc. | Licensing agreement between ZIOPHARM and Precigen 2018 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreement, percentage of development costs for which responsible |  |  |  |  |  | 80.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreement, percentage of operating profits to be received |  |  |  |  |  | 80.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
License agreement, royalty due, aggregated |  |  |  |  |  | $ 50,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ZIOPHARM Oncology, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reacquisition of in-process research and development |  |  |  |  |  | 109,047,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ZIOPHARM Oncology, Inc. | Collaboration and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement, consideration received, value |  |  |  |  |  | 100,000 |  |  |  |  |  |  | $ 17,457,000 |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 18,330,000 |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 51,084,000 |
Revenues |  |  |  |  |  | 500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 200,000 | 2,171,000 | 16,298,000 |  |  |  |  |  |  |
ZIOPHARM Oncology, Inc. | Collaboration and licensing agreements | Reacquired in-process research & development |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 49,329,000 |
ZIOPHARM Oncology, Inc. | Collaboration and licensing agreements | Transition services |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  | $ 1,855,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,755,000 |
Ares Trading S.A. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reacquisition of in-process research and development |  |  |  | $ 108,527,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares issued for reacquired in-process research and development, shares | shares |  |  |  | 20,640,119 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares issued for reacquired in-process research and development |  |  |  | $ 140,353,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty percentage to be paid to other party |  |  |  | 0.10 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ares Trading S.A. | Collaboration and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement, consideration received, value |  |  |  |  |  |  |  |  |  | $ 115,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  | $ 31,826,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 10,000,000
Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 11,175,000 |  |  |  |  |  |  |
Collaborative agreement, consideration receivable, minimum targets required | target |  |  |  |  |  |  |  |  |  | 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement, consideration receivable, collection period |  |  |  |  |  |  |  |  |  | 2 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ares Trading S.A. | ZIOPHARM Oncology, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement, percent of collaboration payments |  |  |  |  |  |  |  |  |  | 50.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ares Trading S.A. | ZIOPHARM Oncology, Inc. | Collaboration and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to related parties |  |  |  |  |  |  |  |  |  | $ 57,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Oragenics, Inc. | Collaboration and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,053,000 | (564,000) | 1,353,000 |  |  |  |  |  |  |
Collaborative agreement, consideration received, value of convertible promissory note |  |  |  |  |  |  |  |  | $ 5,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized from previously deferred balances | $ 2,823,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Intrexon T1D Partners, LLC | Collaboration and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement, consideration received, value |  |  |  |  |  |  | $ 10,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 2,502,000 |  |  |  |  |  |  |
Intrexon Energy Partners, LLC | Collaboration and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement, consideration received, value |  |  |  |  |  |  |  |  |  |  | $ 25,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 | 2,596,000 | 6,929,000 |  |  |  |  |  |  |
Required notice period for voluntary termination of collaborative agreement |  |  |  |  |  |  |  |  |  |  | 90 days |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Intrexon Energy Partners II, LLC | Collaboration and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement, consideration received, value |  |  |  |  |  |  |  | $ 18,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 | 1,217,000 | 2,998,000 |  |  |  |  |  |  |
Required notice period for voluntary termination of collaborative agreement |  |  |  |  |  |  |  | 90 days |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Castle Creek Biosciences, Inc. | Collaboration and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement, consideration received, value |  |  |  |  |  |  |  |  |  |  |  | $ 7,576,000 |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 7,612,000 |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 17,810,000 | 3,713,000 | $ 1,394,000 |  |  |  |  |  |  |
Collaborative agreement, consideration received, cash |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 3,750,000 |  |  |  |  |  |  |  |
Royalty rate as a percentage of net sales, tier 1 |  | 7.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Level of net sales at which royalty rate changes to tier 2 |  | $ 25,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 25,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty rate as a percentage of net sales, tier 2 |  | 14.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized from previously deferred balances |  |  | $ 10,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Exotech, Inc.; AD Skincare, Inc.; and Thrive Agrobiotics, Inc. | Collaboration and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement, consideration received, value |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 11,000,000 |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 6,993,000 |  |
CRS Bio, Inc.; Genten Therapeutics, Inc.; and Relive Genetics, Inc. | Collaboration and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement, consideration received, value |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 10,933,000 |  |  |  |  |  |
Intrexon T1D Partners, LLC |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  | 8,517,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reacquisition of in-process research and development |  |  |  |  | $ 10,453,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares issued for reacquired in-process research and development, shares | shares |  |  |  |  | 1,933,737 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares issued for reacquired in-process research and development |  |  |  |  | $ 18,970,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ownership interest |  |  |  |  | 100.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Genten Therapeutics, CRS Bio, and Relieve Genetics |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ownership interest |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 100.00% |
ZIOPHARM Oncology, Inc. | Preferred stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration Agreements [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair value of assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 158,376,000 |

X
- Definition Collaboration Agreement Termination Notice Period + References No definition available. + Details
Name: | pgen_CollaborationAgreementTerminationNoticePeriod
Namespace Prefix: | pgen_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaboration Agreements [Line Items] + References No definition available. + Details
Name: | pgen_CollaborationAgreementsLineItems
Namespace Prefix: | pgen_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percent of collaboration payments received pursuant to a collaboration agreement for upfront fees, milestones and royalties which will be paid to another party. + References No definition available. + Details
Name: | pgen_CollaborationArrangementPercentOfCollaborationPayments
Namespace Prefix: | pgen_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The period over which the consideration is owed to the entity under a collaboration agreement. + References No definition available. + Details
Name: | pgen_CollaborativeArrangementConsiderationReceivableCollectionPeriod
Namespace Prefix: | pgen_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of targets selected by a collaborator under a collaboration agreement which result in consideration owed to the entity. + References No definition available. + Details
Name: | pgen_CollaborativeArrangementConsiderationReceivableMinimumTargetsRequired
Namespace Prefix: | pgen_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Arrangement Consideration Received Cash + References No definition available. + Details
Name: | pgen_CollaborativeArrangementConsiderationReceivedCash
Namespace Prefix: | pgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Value of consideration received by the entity for collaboration + References No definition available. + Details
Name: | pgen_CollaborativeArrangementConsiderationReceivedValue
Namespace Prefix: | pgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Value of promissory note received as consideration of collaboration agreement which can be settled in cash or common stock. + References No definition available. + Details
Name: | pgen_CollaborativeArrangementConsiderationReceivedValueOfConvertiblePromissoryNote
Namespace Prefix: | pgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Level of net sales, as defined in the collaboration agreement, at which the royalty rate changes to tier 2. + References No definition available. + Details
Name: | pgen_CollaborativeArrangementNetSalesAtWhichRoyaltyRateChangesToTierTwo
Namespace Prefix: | pgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Percentage of net sales, as defined in the collaboration agreement, used to calculate royalty payments to which entity is entitled, tier 1. + References No definition available. + Details
Name: | pgen_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierOne
Namespace Prefix: | pgen_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of net sales, as defined in the collaboration agreement, used to calculate royalty payments to which entity is entitled, tier 2. + References No definition available. + Details
Name: | pgen_CollaborativeArrangementRoyaltiesAsPercentageOfNetSalesTierTwo
Namespace Prefix: | pgen_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Annual licensing fee due under licensing agreement. + References No definition available. + Details
Name: | pgen_LicenseAgreementAnnualFee
Namespace Prefix: | pgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of exclusively licensed products under a licensing agreement. + References No definition available. + Details
Name: | pgen_LicenseAgreementNumberofExclusivelyLicensedProducts
Namespace Prefix: | pgen_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage of development costs for which an entity is responsible under a licensing agreement. + References No definition available. + Details
Name: | pgen_LicenseAgreementPercentageofDevelopmentCostsForWhichResponsible
Namespace Prefix: | pgen_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition License Agreement, Percentage of Sublicensing Income + References No definition available. + Details
Name: | pgen_LicenseAgreementPercentageofSublicensingIncome
Namespace Prefix: | pgen_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of quarterly installments in which historical costs will be reimbursed under licensing agreement. + References No definition available. + Details
Name: | pgen_LicenseAgreementReimbursementofHistoricalCostsNumberofQuarterlyInstallments
Namespace Prefix: | pgen_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Royalty amount due under licensing agreement, aggregated. + References No definition available. + Details
Name: | pgen_LicenseAgreementRoyaltyDueAggregated
Namespace Prefix: | pgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The period following a triggering event after which a licensing agreement will be terminated, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | pgen_LicenseAgreementTerminationPeriodFollowingTriggeringEvent
Namespace Prefix: | pgen_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage of operating profits to be received by an entity under a licensing agreement. + References No definition available. + Details
Name: | pgen_LicensingAgreementPercentageofOperatingProfitstoBeReceived
Namespace Prefix: | pgen_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Reimbursement of historical costs to which an entity is entitled under a licensing agreement. + References No definition available. + Details
Name: | pgen_LicensingAgreementReimbursementofHistoricalCosts
Namespace Prefix: | pgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Milestone Payments Required Upon Successful Achievement Aggregated + References No definition available. + Details
Name: | pgen_MilestonePaymentsRequiredUponSuccessfulAchievementAggregated
Namespace Prefix: | pgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of potential future milestone payments to be received under agreement per product + References No definition available. + Details
Name: | pgen_MilestonePaymentsRequiredUponSuccessfulAchievementPerProduct
Namespace Prefix: | pgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Cash outflows for payments made to related parties. + References No definition available. + Details
Name: | pgen_PaymentsToRelatedParties
Namespace Prefix: | pgen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The percentage of ownership of common stock or equity participation in a related party. + References No definition available. + Details
Name: | pgen_RelatedPartyOwnershipInterest
Namespace Prefix: | pgen_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage royalty payable to another party as defined in applicable agreement. + References No definition available. + Details
Name: | pgen_RoyaltyPercentageToBePaidtoOtherParty
Namespace Prefix: | pgen_
Data Type: | xbrli:pureItemType
Balance Type: | na
Period Type: | duration

X
- Definition The period following the effective date of the licensing agreement during which costs incurred to transition knowledge and materials will be reimbursed by third party, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | pgen_TransitionPeriodDuringWhichCostsWillBeReimbursed
Namespace Prefix: | pgen_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 + Details
Name: | us-gaap_AssetsFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275 + Details
Name: | us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination. + References No definition available. + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination. + References No definition available. + Details
Name: | us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=pgen_LicensingAgreementBetweenZIOPHARMandPrecigen2018Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=pgen_UpfrontAndMilestonePaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=pgen_ZiopharmMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=pgen_ZiopharmMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DeferredRevenueArrangementTypeAxis=pgen_ReacquiredInProcessResearchDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DeferredRevenueArrangementTypeAxis=pgen_TransitionServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=pgen_AresTradingS.A.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pgen_ZiopharmMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=pgen_OragenicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=pgen_IntrexonT1DPartnersLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=pgen_IntrexonEnergyPartnersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=pgen_IntrexonEnergyPartnersIILLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=pgen_CastleCreekBiosciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=pgen_ExotechADSkincareAndThriveAgrobioticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=pgen_CRSBioInc.GentenTherapeuticsInc.andReliveGeneticsInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pgen_IntrexonT1DPartnersLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pgen_GentenTherapeuticsCRSBioAndRelieveGeneticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_InvestmentTypeAxis=pgen_ZiopharmMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByAssetClassAxis=us-gaap_PreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |